Yu-Wang Liu

Title: Yu-Wang Liu: Innovator in Alzheimer's Disease Research

Introduction

Yu-Wang Liu is a prominent inventor based in Santa Clara, CA, known for his significant contributions to the field of Alzheimer's disease research. He holds a total of four patents that focus on innovative methods to inhibit the production of amyloid-beta, a key factor in the progression of Alzheimer's disease.

Latest Patents

One of his latest patents is titled "Inhibition of Aβ production by β-secretase BACE2." This invention is based on the discovery that BACE2, a homolog of β-secretase BACE, can stimulate the processing of APP in a non-amyloidogenic pathway, thereby reducing the levels of Aβ. The methods and means provided in this patent offer potential candidates for treating Alzheimer's disease and other neurological disorders by decreasing β-amyloid deposit formation. Another notable patent is "β-secretase and modulation of β-secretase activity." This invention introduces a novel β-secretase and outlines a method for its partial purification. It also describes its application in assays to screen for potential drug candidates against Alzheimer's disease and other neurological conditions.

Career Highlights

Throughout his career, Yu-Wang Liu has worked with notable companies such as Scios Inc. and Eli Lilly and Company. His work has significantly advanced the understanding of β-secretase and its role in Alzheimer's disease, contributing to the development of potential therapeutic strategies.

Collaborations

Yu-Wang Liu has collaborated with esteemed colleagues, including Barbara Cordell and Diana Hom Quon, to further his research and innovations in the field.

Conclusion

Yu-Wang Liu's innovative work in Alzheimer's disease research has the potential to lead to significant advancements in treatment options. His patents reflect a deep understanding of the mechanisms involved in the disease, paving the way for future discoveries.